Abstract 2659
Background
The PI3K/AKT pathway activation is an early event in HNSCC and an independent marker of poor outcome that seems to be involved in resistance to cetuximab. BKM120 is an oral, pan-Class I PI3K inhibitor that inhibits tumor growth in HNSCC xenografts.
Methods
This Phase II evaluates the clinical benefit of BKM120 (100mg/d, po) in 2 parallel cohorts of HNSCC pts with or without mutation in PI3KCA. Eligible pts progressed after platin and cetuximab or anti-EGFR therapy, and had documented PIK3CA status (exons 9 and 20). The primary endpoint was 2-month Disease Control Rate (DCR2m) as per RECIST 1.1. Secondary endpoints were ORR, PFS, OS, and safety. Blood and tumor samples were obtained for pharmacodynamics (PD). Imaging data were centrally reviewed. Considering that BKM120 would be uninteresting if DCR2m ≤ 10% and promising if ≥ 30% and using Simon's optimal two-stage design (α: 5% unilateral, power: 90%), 7 successes/35 evaluable pts were required for each cohort. Only results of the cohort without PI3KCA mutation are presented. .
Results
36 HNSCC pts without PI3KCA mutation (median age: 58.6 yrs) received at least one dose of BKM120. They were heavily pretreated (33% with at least 3 previous lines). Median treatment duration was 8 wks [min-max: 4 d-55.9 wks]. At the end of 2nd Simon's Stage, the DCR2m was 38.9% (14/36pts). No OR was observed. The most common related AE (>25%) included hyperglycemia, asthenia, anxiety, depression, lymphopenia, anemia, leucocyte increase, hematocrit decrease, nausea and diarrhea. 20 pts (55.6%) presented at least one related AE ≥ Grade 3 (>5%: hyperglycemia, lymphopenia, asthenia, Na or K decrease) and 10 pts (27.8%) prematurely discontinued BKM120 due to an AE. 11pts (30.6%) experienced a related SAE including 3 SUSARs (1 fatal hyperglycemic coma, 1 death of uncertain relationship, 1 severe dehydration). PFS, OS and PD data will be presented at the meeting. Cohort with PI3KCA mutation is ongoing (n = 17).
Conclusions
BKM120 deserves further investigation in relapsing HNSCC pts without PI3KCA mutation, nevertheless with close monitoring of metabolic tolerance.
Clinical trial identification
NCT01737450
Legal entity responsible for the study
Centre Leon Bérard
Funding
Institut National du Cancer and Fondation ARC
Disclosure
All authors have declared no conflicts of interest.